 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
12 News |  |
- || KA2237 / Karus Therap
P1 data, Preclinical, Journal: Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. (Pubmed Central) - Apr 15, 2022
P1
Thirty-three percent discontinued treatment due to adverse events. KA2237 induced objective responses in indolent and aggressive lymphoma (overall response rate 37%; complete response n = 4, partial response n = 3).
- ||||| KA2237 / Karus Therap
Clinical: Our study done in collaboration with Karus Therapeutics and led by Dr. Nastoupil found KA2237 (dual p110β/p110δ inhibitor) to be an effective therapeutic option for patients with refractory B-cell lymphoma without an acceptable standard of care option. https://t.co/8hnz5bgSFC (Twitter) - Aug 10, 2021
- | KA2237 / Karus Therap
Journal: Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. (Pubmed Central) - May 15, 2021
In addition, combining KA2237 with currently available chemotherapeutic agents synergistically inhibited metabolic growth. This study elucidates the compensatory upregulated PI3K/AKT axis that emerges in ibrutinib-resistant cells.
- KA2237 / Karus, Rituxan (rituximab) / Roche, Biogen
Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5835;
P1
The recommended phase II dose is 200mg daily . The findings of this study support the further evaluation of KA2237.
- || CVL237 / Convalife
Trial completion, Enrollment change, Trial completion date: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Feb 6, 2019
P1, N=23, Completed, Sponsor: Karus Therapeutics Limited
The findings of this study support the further evaluation of KA2237. Recruiting --> Completed | N=53 --> 23 | Trial completion date: May 2019 --> Dec 2018
- | CVL237 / Convalife
Trial primary completion date: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Aug 27, 2018
P1, N=53, Recruiting, Sponsor: Karus Therapeutics Limited
Recruiting --> Completed | N=53 --> 23 | Trial completion date: May 2019 --> Dec 2018 Trial primary completion date: May 2018 --> Oct 2018
- || CVL237 / Convalife
Enrollment change: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Dec 23, 2016
P1, N=53, Recruiting, Sponsor: Karus Therapeutics Limited
Trial primary completion date: May 2018 --> Oct 2018 N=38 --> 53
- CVL237 / Convalife
Enrollment open: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Aug 11, 2016
P1, N=38, Recruiting, Sponsor: Karus Therapeutics Limited
N=38 --> 53 Not yet recruiting --> Recruiting
- CVL237 / Convalife
New P1 trial: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110?/? Inhibitor) In B Cell Lymphoma (clinicaltrials.gov) - Feb 10, 2016
P1, N=38, Not yet recruiting, Sponsor: Karus Therapeutics Limited